IR logo

Ingersoll Rand

IR · What the business does, what can go wrong, and how options sellers approach it

What it does

Ingersoll Rand makes flow and compression equipment used across many industries. Its products include air compressors, blowers, vacuum pumps, and fluid management products such as pumps and related equipment.

The company reports in two parts: industrial technologies and services, and precision and science technologies. The first serves factories and industrial plants. The second covers more specialized products for medical, laboratory, and energy applications.

How it makes money

Ingersoll Rand sells equipment to industrial customers, then earns additional revenue from aftermarket parts, maintenance, repair, and service over the equipment's life. Aftermarket work tends to be steadier than new equipment orders because installed machines need ongoing upkeep.

The company has also grown by acquiring smaller businesses and folding them into its portfolio, an ongoing part of its strategy.

Why investors own it

  • Essential products: Compressors and pumps are often embedded in customer operations, so they are repaired and replaced rather than dropped.
  • Recurring revenue: Service and parts add a more stable layer on top of cyclical equipment sales.
  • Diverse end markets: Exposure to many industries can soften weakness in any single one.
  • Capital allocation: Investors often watch how management balances acquisitions, debt, and share repurchases.

What can go wrong

  • Economic cycles: Customers often delay equipment purchases when growth slows.
  • Acquisition risk: Deals can be overpriced or hard to integrate, and related debt adds risk.
  • Input costs: Higher material and labor costs can squeeze margins.
  • Competition: Global industrial rivals compete in each product line.
  • Currency and trade: Exchange rates, tariffs, and regional slowdowns can hurt results.

What to watch

  • Orders and backlog
  • Organic revenue growth (excluding acquisitions and currency)
  • Aftermarket and service share of sales
  • Adjusted EBITDA margin
  • Free cash flow conversion
  • Net debt and leverage
  • Acquisition activity and integration progress
  • Industrial activity indicators, such as manufacturing surveys

Options income angle

Options on IR trade across multiple expirations, with liquidity usually adequate for a large-cap industrial, though thinner than for the most heavily traded names.

Implied volatility tends to rise around quarterly earnings, when orders and guidance can move the shares, and when expectations for industrial demand shift.

One caution: selling premium ahead of earnings can mean absorbing a sharp price gap. Covered calls can cap gains in a rally, and cash-secured puts can leave you owning the stock after a decline.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 17, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Ingersoll Rand grew revenue in 2025 mainly by buying other businesses, while organic sales (growth excluding acquisitions and currency) fell. Reported profit dropped sharply because of non-cash write-downs tied to the ILC Dover acquisition and an equity investment. The filing also shows a heavily acquisition-built balance sheet and a debt load of $4,784.7 million.

How the business did

  • Revenues were $7,650.9 million, up 5.7% from $7,235.0 million. Acquisitions added $419.9 million and currency added $92.0 million, while organic revenues were lower by $96.0 million.
  • Net income fell to $588.8 million from $846.3 million. Management attributes this mainly to impairments (write-downs of an asset's recorded value) of goodwill and other intangible assets, plus an impairment of an equity method investment. Goodwill impairment was $229.7 million, in the Biopharma and Aerospace & Defense units.
  • Industrial Technologies and Services revenues rose 4.1%, but organic revenues fell 1.8% and segment Adjusted EBITDA margin slipped to 28.9% from 30.2%. Precision and Science Technologies revenues rose 12.5%, with margin up to 30.0% from 29.6%.
  • Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization and other items management excludes) was $2,093.8 million. Margin eased to 27.4% from 27.9%, which management ties to input cost inflation and product mix. Tariff-related pricing was set to offset tariff cost increases one for one.
  • Free cash flow (operating cash flow less capital expenditures) was $1,220.1 million. The company spent $1,018.0 million on treasury stock purchases and $31.8 million on dividends.

Risks specific to this company

  • Goodwill concentration: Goodwill and other intangible assets were $12.7 billion, or 70%, of total assets. Further write-downs could follow if forecasts or discount rates change, and the Life Sciences reporting unit had a cushion of 30%.
  • Debt: Total indebtedness was $4,784.7 million, with some borrowings at variable rates through swaps. Higher interest rates would raise debt costs, and the filing notes that debt service takes cash from other uses.
  • International and China exposure: 58% of revenues came from outside the United States. The filing singles out China, where the company has material operations, supply chain dependencies and material cash balances.
  • Tariffs and materials: Steel and aluminum tariffs have raised costs for some materials and components. The company also uses single sources for certain iron castings, motors and other key components.
  • Fixed-price custom projects: Substantially all custom engineered product contracts are at a fixed price, so cost overruns, delays or liquidated damages could erase profit or cause losses.
  • Customer consolidation: Consolidation or vertical integration among customers is flagged as a particular concern in the life sciences and aerospace end markets, where larger customers may push prices down.

What management is watching

  • Capital expenditures are expected to be approximately 2% of consolidated revenues in 2026.
  • Demand in Industrial Technologies and Services is tied to industrial capacity utilization, which the filing says above 80% has historically signaled a strong environment. In parts of Precision and Science Technologies, management points to growth in healthcare spending and an aging population.
  • Management points investors to Adjusted EBITDA, Adjusted Net Income and Free Cash Flow, which are non-GAAP measures that adjust the standard accounting results.
  • Aftermarket parts, consumables and services were 36.5% of total revenue, and management describes this as a recurring stream from the installed base.
  • Capital uses named include acquisitions, debt service, capital expenditures, share repurchases and dividends. Restructuring charges were $51.4 million, and the filing says future initiatives may cost more than estimated.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 30, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Ingersoll Rand reported revenues of $2,064.9 million for the quarter ended September 30, 2026, up 5.6% from a year earlier. Net income of $671.6 million was lifted by a one-time recovery of acquisition related losses, net of $380.1 million tied to the ILC Dover deal. The underlying picture is better shown by Adjusted EBITDA of $584.4 million, which itself included $32.3 million of IEEPA tariff refunds.

How the business did

  • Revenue: Quarterly revenues were $2,064.9 million versus $1,955.0 million, driven by organic growth of $76.0 million, acquisitions of $28.2 million and currency of $5.7 million. Nine-month revenues were $5,960.9 million, up 7.2%.
  • Profit: Net income for nine months was $1,123.4 million versus $320.4 million. The prior-year period carried goodwill and intangible impairments and an equity investment loss that did not recur. Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, with one-off items removed) margin was 28.3% for the quarter versus 27.9%, but 26.4% for nine months versus 27.2%, which management attributed to input cost inflation and product mix. The quarter's tax rate of 7.4% reflected a valuation allowance release and a nontaxable settlement.
  • Segments: Industrial Technologies and Services had orders of $1,897.5 million, up 24.7%, driven by several large long-cycle engineered-to-order (ETO) projects, and a segment margin of 29.4%. Precision and Science Technologies had revenues of $444.9 million and a segment margin of 34.3% versus 30.8%.
  • Cash and capital return: Nine-month operating cash flow was $1,143.4 million and free cash flow (operating cash flow less capital expenditures) was $1,055.6 million. These figures include $187.5 million collected from the ILC Dover settlement and $42.6 million of tariff refunds. Financing outflows included treasury stock purchases of $689.1 million and dividends of $23.3 million.

What management is watching

  • Tariffs: Management says tariff developments have not had a material impact on results to date, but it cannot predict future effects and they could be material. IEEPA tariff refunds helped gross profit and cash flow this quarter.
  • Data center entry: Segment orders include an approximately $195 million ETO data center infrastructure order. Its quoted margin is below the segment profile margin, which management describes as a strategic step into that end market.
  • Debt maturity: The 2027 Notes mature in the second quarter of 2027, so short-term borrowings and current maturities rose to $700.2 million from $1.4 million. Management expects to retire or refinance debt from operating cash flow, its Commercial Paper Program and its Revolving Credit Facility, which had $2,600.0 million of unused availability.
  • Measures to follow: Management points investors to Adjusted EBITDA, Adjusted Net Income and Free Cash Flow. The sections provided give no numeric full-year outlook.

Follow IR in Kortex

The Kortex app shows IR's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.